Cancer Crosslinks 2014, January 23, was the 6th edition of this annual oncology conference bringing together hematologists, oncologists and the industry in Norway.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 325 entries.
Entries by oslocancer
BerGenBio AS, an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013.
Immunotherapy specialist Targovax reaches Phase IIa in operable pancreatic cancer with its TG01 immunotherapy. RAS specific immune responses were induced in all 6 patients in Phase I, and no substantial side effects were observed in the patients. The clinical trial has now expanded from Norway to two sites in the UK
May 2015 is THE grand opening of Oslo Cancer Cluster Innovation Park and Oslo Cancer Cluster Incubator. Would you like to join us in the fight against cancer by being part of a power centre for developing innovative cancer treatment? Contact us now, and see what we may offer you as a tenant in the Innovation Park or the Incubator.
Oslo Cancer Cluster and French partner Cancer-Bio-Santé are joining forces with SwedenBio to offer the global Life Science industry the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering. Already now oncology biotechs, early stage companies and academics may submit an application for presenting at NLSDays-ECCP […]
The Norwegian Research Council recently granted BerGenBio, PCI Biotech, Lytix Biopharma, Oncoinvent and Ultimovacs – all Oslo Cancer Cluster member companies – funding through the Programme for User-Driven Research Based Innovation (BIA).
Friday January 31 Oslo Cancer Cluster, SINTEF, NTNU, Oslo University Hospital and the Norwegian Cancer Society invite Norwegian media and other interested parties to join a breakfast seminar on nano cancer medicine. The seminar is held in conjunction with 12 similair events across the whole of Europe in relation to Nano World Cancer Day. Below […]
Six biology students from Ullern High School were selected to intern at the Department of Tumor Biology at Oslo University Hospital in week 50. This is the fourth time the department has had students from Ullern interning, says researcher Birgit Engesæter. Together with her research colleague Siri Tveito, she is in charge of the students […]
The newly employed Head of Biotech Investments in The Norwegian Cancer Society, Sigrid Fossheim, has already had several meetings with potential oncology companies to invest in. – We aim to make our first investment before the Summer of 2014, says Fossheim.
The six year evaluation of Oslo Cancer Cluster as a Norwegian Centre of Expertise concludes that Oslo Cancer Cluster is a strong biotech cluster, well positioned within the global oncology industry. “This plays well with our ambition to take the step up a level and become a Global Centre of Excellence,” says Jónas Einarsson, acting CEO […]
Despite keen competition from other outstanding medical research groups, Oslo Cancer Cluster Board members Professor Ragnhild A. Lothe and Professor Rolf Bjerkvig have won the competition for funds for new K.G. Jebsen centres in the field of medicine – a long side John-Bjarne Hansen.
Oslo Cancer Cluster member BerGenBio announce that preclinical studies on the agent BGB324 may be effective as new treatment for patients with drug resistant Chronic Myeloid Leukemia (CML). The data was presented in a poster at the Annual Meeting of the American Society of Hematology (ASH) early December.
December 11th 2013, Oslo Cancer Cluster, Oslo Medtech and Nansen Neuroscience Network launched a proposal for a new financing mechanism to stimulate innovation from the health- and biotech industry.
Oslo Cancer Cluster member Bayer HealthCare announced Monday December 9th that they just received the marketing approval for Xofigo® (radium Ra 223 dichloride) by the Norwegian Medicines Agency. The approval came approximately one month after the European Commission granted marketing authorization in the EU for Xofigo® on November 15 2013.
Oslo Cancer Cluster member Lytix Biopharma AS has completed a successful issue that was subscribed shares of over 50 million NOK.
Horizon 2020 is the new European Framework Program for Research and Innovation. Oslo Cancer Cluster encourage our members to take a closer look at the possibilities Horizon 2020 represents for funding R&D oncology projects and also taking part in international networks.
Inven2 grants exclusive worldwide license to its epidermal growth factor receptor (EGFR) inhibitors patent portfolio to Merck. Researchers and clinicians at Sørlandet Hospital have discovered that the EGFR inhibitors may play a vital role as a pain reliever for so called neuropathic pain.
Algeta and Bayer have received marketing authorisation from the European Commission for Xofigo® for the treatment of prostate cancer patients with bone metastases.
Three Oslo Cancer Cluster SME`s emerged as the winners of the Immuno-Oncology Innovation Call. Oncoinvent was as a clear number one of the 10 applications received.
The 2013 year’s grant to cancer research in Norway, 160 million NOK (EUR 20 M) is the largest grant the Norwegian Cancer Society has ever given.
The new government of Norway has launched their political platform. Oslo Cancer Cluster have reviewed the political platform document. We are overall very pleased with the initiatives that concerns research, knowledge, education, business and R&D.
Oslo Cancer Cluster was the proud host of a press conference in early October, where two of the Nordic region’s largest governmental venture investors Investinor and Industrifonden announced their NOK million 90 investment in Swedish biotech Pharmalink.
Life Technologies Corporation has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Both Novartis and Life Technologies are member of Oslo Cancer Cluster.
Now in its fourth year as a member of the Oslo Cancer Cluster, Ockham Oncology unveils its stronger global oncology expertise, as a fully integrated, pure oncology-focused international partner.
Oslo Cancer Cluster, the Norwegian Cancer Society and the Association of the Pharmaceutical Industry in Norway join forces in pushing for a new cancer drugs fund. The purpose of the fund is to ensure equal and quicker access to new approved cancer drugs in Norway. A cancer drugs fund would cover the costs of […]
Contact Team >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.